InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-06 | 2026-03-10 | Bailey A Robert D | EVP & Chief Legal Officer | Purchase | 14.6K | $17.15 | $250K | 231.9K | View ↗ | |
| 2026-03-06 | 2026-03-10 | Eldessouky Sam | EVP and CFO | Purchase | 4,000 | $17.13 | $69K | 403.1K | View ↗ | |
| 2026-03-06 | 2026-03-10 | SAUNDERS BRENT L | Director & CEO and Chairman of the Board | Purchase | 14.7K | $17.14 | $252K | 966.6K | View ↗ | |
| 2026-03-03 | 2026-03-04 | Ross Thomas W. Sr. | Director | Purchase | 4,500 | $17.68 | $80K | 64.9K | View ↗ | |
| 2026-03-02 | 2026-03-03 | Alfonso Eduardo | Director | Purchase | 4,300 | $17.90 | $77K | 9,555 | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | $21.0M+23.5% | $17.0M+13.3% | $15.0M-31.8% | $22.0M-21.4% | $28.0M |
| Selling, general and administrative (Note 3) | $2.23B+7.3% | $2.08B+19.9% | $1.74B+17.5% | $1.48B+6.4% | $1.39B |
| Research and development | $371.0M+8.2% | $343.0M+5.9% | $324.0M+5.5% | $307.0M+13.3% | $271.0M |
| Amortization of intangible assets | $258.0M-10.4% | $288.0M+20.0% | $240.0M-1.6% | $244.0M-16.4% | $292.0M |
| Other expense, net | $75.0M+70.5% | $44.0M-40.5% | $74.0M+469.2% | $13.0M-23.5% | $17.0M |
| Total expenses | $4.99B+7.8% | $4.63B+15.3% | $4.02B+12.8% | $3.56B+3.6% | $3.44B |
| Operating income | $113.0M-30.2% | $162.0M+24.6% | $130.0M-37.2% | $207.0M-37.1% | $329.0M |
| Interest income | $12.0M-20.0% | $15.0M+0.0% | $15.0M+150.0% | $6.0M | $0 |
| Interest expense | -$421.0M-5.5% | -$399.0M-41.0% | -$283.0M-93.8% | -$146.0M | $0 |
| Loss on extinguishment of debt | -$6.0M | $0 | $0 | — | — |
| Foreign exchange and other | -$15.0M-25.0% | -$12.0M+57.1% | -$28.0M-566.7% | $6.0M+154.5% | -$11.0M |
| Loss before provision for income taxes | -$317.0M-35.5% | -$234.0M-41.0% | -$166.0M-327.4% | $73.0M-77.0% | $318.0M |
| Provision for income taxes | -$35.0M+50.7% | -$71.0M+13.4% | -$82.0M-41.4% | -$58.0M+53.6% | -$125.0M |
| Net loss | -$352.0M-15.4% | -$305.0M-23.0% | -$248.0M-1753.3% | $15.0M-92.2% | $193.0M |
| Net income attributable to noncontrolling interest | -$8.0M+33.3% | -$12.0M+0.0% | -$12.0M-33.3% | -$9.0M+18.2% | -$11.0M |
| Net loss attributable to Bausch + Lomb Corporation | -$360.0M-13.6% | -$317.0M-21.9% | -$260.0M-4433.3% | $6.0M-96.7% | $182.0M |
| Basic loss per share attributable to Bausch + Lomb Corporation (in usd per share) | -$1.0M-13.3% | -$900K-21.6% | -$740K-3800.0% | $20K-96.2% | $520K |
| Diluted loss per share attributable to Bausch + Lomb Corporation (in usd per share) | -$1.0M-13.3% | -$900K-21.6% | -$740K-3800.0% | $20K-96.2% | $520K |
| Basic weighted-average common shares (in shares) | $353.8M+0.6% | $351.8M+0.4% | $350.5M+0.1% | $350.0M+0.0% | $350.0M |
| Diluted weighted-average common shares (in shares) | $353.8M+0.6% | $351.8M+0.4% | $350.5M+0.1% | $350.2M+0.1% | $350.0M |
| Product sales | |||||
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues | $5.0M+25.0% | $4.0M+100.0% | $2.0M-75.0% | $8.0M-99.5% | $1.46B |
| Other revenues | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Most and least shorted mid- to mega-cap healthcare stocks at the end of May
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care - Slideshow
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States